• 1
    Swerdlow S, Campo E, Harris N et al. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC), 2008.
  • 2
    de The G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 1993; 9: 3816.
  • 3
    Tajima K, Tominaga S, Suchi T, Fukui H, Komoda H, Hinuma Y. HTLV-I carriers among migrants from an ATL-endemic area to ATL non-endemic metropolitan areas in Japan. Int J Cancer 1986; 37: 3837.
  • 4
    Tokudome S, Tokunaga O, Shimamoto Y et al. Incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type I carriers in Saga, Japan. Cancer Res 1989; 49: 2268.
  • 5
    Yamamoto K, Utsunomiya A, Tobinai K et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28: 15918.
  • 6
    Tsukasaki K, Utsunomiya A, Fukuda H et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25: 545864.
  • 7
    Hino S, Katamine S, Miyata H, Tsuji Y, Yamabe T, Miyamoto T. Primary prevention of HTLV-1 in Japan. Leukemia 1997; 11(Suppl 3): 579.
  • 8
    Yoshida M. Mechanism of transcriptional activation of viral and cellular genes by oncogenic protein of HTLV-1. Leukemia 1994; 8(Suppl 1): S513.
  • 9
    Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol 1991; 79: 42837.
  • 10
    Seiki M, Hattori S, Hirayama Y, Yoshida M. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci USA 1983; 80: 361822.
  • 11
    Matsuda T, Marugame T, Kamo KI, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2011; 42: 13947.
  • 12
    Curado M, Edwards B, Shin Het al., eds. Cancer Incidence in Five Continents, Vol. IX. Lyon: IARC Scientific Publications, 2007.
  • 13
    Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969–2009) Surveillance Research Program. Released January 2011 edn. National Cancer Institute, DCCPS; Cancer Statistics Branch.
  • 14
    Surveillance, Epidemiology, and End Results (SEER) Program. Surveillance Research Program. Released April 2011 edn: National Cancer Institute, DCCPS; Cancer Statistics Branch.
  • 15
    Bray F, Guilloux A, Sankila R, Parkin DM. Practical implications of imposing a new world standard population. Cancer Causes Control 2002; 13: 17582.
  • 16
    Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 33551.
  • 17
    Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol 2012; 84: 32735.
  • 18
    Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7: 26681.
  • 19
    Ohshima K. Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci 2007; 98: 7728.
  • 20
    Mueller N. The epidemiology of HTLV-I infection. Cancer Causes Control 1991; 2: 3752.